It was doomed before it ever began. Sadly, there are so many hidden disadvantages of Medicare Advantage plans.
Like its predecessor, Medicare+Choice, the current Medicare “Advantage” system is a shimmering mirage of cheap co-pays, cheaper hospital stays, and the quaint notion that it’s “free of some anonymous Washington bureaucrat pushing you around.”
At least that’s what the pushers of this chimera told us. Humana, UnitedHealthcare, and the rest touted big discounts on dental, glasses, and hearing aids. Deals so good we found ourselves saying, “What do we have to lose?”
A lot, it turns out.
Born of greed, audacious political payback, and Conservative dreams of finally killing “socialized medicine,” then patched together by drug and health insurance lobbyists, the 415-page 2003 Medicare Prescription Drug, Improvement, and Modernization Act has indeed improved a lot of Medicare beneficiaries.
Part D Can Cost You Big
Today, thanks to Part D, only 8.5 percent of us lack drug coverage. Of the 8.7-million currently enrolled in private Medicare Advantage (MA) plans (Part C), most say they are pleased with the benefits formerly covered under traditional Medicare (Parts A and B).
At least until they get sick.
Then, as the Commonwealth Fund and the Kaiser Family Foundation reported in August, they are likely to pay $300/mo. more for drugs through Part D than is paid by folks getting their medicine through the VA or employer-based health plans. Further, according to the Medicare Rights Center, the sickest of those enrolled in MA pay far more for health care than they’d pay for traditional Medicare.
- “People who receive chemotherapy, inpatient hospital care, home health care, and skilled nursing care through private health plans incur greater out-of-pocket costs than they would through the public Medicare program and cannot insure themselves against these prohibitive costs.”
Congress Cozy with Profiteers
And look at the cost. This year, according to the Medicare Rights Center, MA plans will cost taxpayers about $75-billion. Those with Medicare will pay an additional $74-billion in Part B premiums – above the cost of care under traditional Medicare funding – in subsidies to Humana, WellCare, and the rest.
Still, until Democrats took over Congress last year, no one paid much attention to such wretched excess. Most assumed that the managed-care business was “wringing the waste out of Medicare,” just as the Republicans promised.
Oh, there were signs.
A year ago, Humana’s profits tripled, then doubled again this year. All because of new Medicare drug-plan members. Executive salaries, too, reflected this extravagance. In 2005, the CEO of UnitedHealth Group, AARP’s health insurance arm, took home $135.5-million – $82,121 an hour. Aetna’s CEO, $57.5-million. Cigna’s CEO, 42.1-million.
Now, two new reports help bring it all into focus.
Last month, investigators from the Government Accountability Office (GAO) found that, besides failing to run effective oversight and enforcement on marketing abuses by Medicare Advantage programs, the Bush administration abandoned statutory requirements to audit at least one-third of the insurance companies each year.
In 2003, when they did take place, Medicare found significant errors at four of five companies audited. Auditors said that insurers kept “$59-million that beneficiaries [should] have received in additional benefits, lower co-payments or lower premiums.” The Bush administration took no action.
The administration did, however, sent dunning letters to more than 135,000 Americans on behalf of the insurance companies, saying they still owed premiums for 2006.
Government More Efficient Than Private Enterprise
Then, earlier this month, Henry Waxman’s (D-CA) House Oversight and Government Reform Committee released a report finding that the Medicare Part D program:
- Suffers from high overhead costs. Sales costs, administrative expenses, etc. will reach $3.6-billion this year. Add $1-billion in profits and you have costs about six times higher than traditional Medicare. (Excessive costs are not due to one-time “start-up” expenses; total costs increased in 2007 from 2006.)
- Fails to negotiate significant drug manufacturer rebates. The 8.1 percent rebates negotiated in 2007 by Part D insurers compares poorly with the 26 percent received in rebates by Medicaid. This alone could have saved almost $15-billion this year.
- Disregards requirements that insurers give Medicare beneficiaries “access to their negotiated prices,” including discounts, rebates, and other price concessions. In other words, it’s your money. But instead of delivering lower drug prices or filling coverage gaps like the donut hole, this year alone a billion dollars will flow in the opposite direction, into drug companies’ pockets.
Nothing’s happened yet.
Predictably, America’s Health Insurance Plans (AHIP) launched a TV campaign á la the Clinton-era’s “Harry and Louise” when threatened by an early version of the now-dead SCHIP bill that would have used MA money to pay for increased health coverage for children.
